org placeholder image

James Callaway

Head of Development at Nuravax

  • LinkedIn

Email Email: j****@armagen.com

phone noPhone Number: (***)-***-****

Dr. Callaway has over 30 years of biopharmaceutical leadership experience. Jim is currently CEO of KalGene, a development stage biotech company targeting Alzheimer's disease with sites in...

Read More

map
NURAVAX

NURAVAX

  • Headquarter Headquarters: 6200 Edinger Ave, Los Angeles, California, 92647, United States
  • Industry Industry Biotechnology
  • website Website nuravax.com
  • description Description
    Our mission is to develop effective and affordable preventive vaccines for Alzheimers disease, Parkinsons disease, and other neurodegenerative disorders. Using our universal vaccine platform ...

    Read More

  • Employees count Employees 11-50
  • Revenue Revenue Under 1 Million
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Nuravax Org Chart and Mapping

Employees

Frequently Asked Questions Regarding James Callaway

Answer: James Callaway works for Nuravax as Head of Development

Answer: James Callaway’s role in Nuravax is Head of Development

Answer: James Callaway's email address is j***@gmail.com

Answer: James Callaway's business email address is j****@armagen.com

Answer: James Callaway’s direct phone number is (***)-***-****

Answer: James Callaway works in the industry of: Biotechnology

Answer: James Callaway is the current Head of Development at Nuravax.... Read More

Answer: James Callaway works Nuravax located at 6200 Edinger Ave, Los Angeles, California, 92647, United States

Answer: Nuravax's Head of Development is James Callaway

Answer: James Callaway contact details:

  • Phone number  :  (***)-***-****
  • Email  :  j****@armagen.com

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access